Sep. 18, 2021

PF-06843195

oral PI3Kα-selective kinase inhibitor prodrug preclinical candidate for breast cancer from mining of prior PI3K inh., SBDD, and opt. J. Med. Chem., Dec. 24, 2020 Pfizer, San Diego, CA

drughunter.com
Drug Hunter Team
Loading...

twitterlinkedinemail

Other molecules you may be interested in